THREE-STEP PLAN TO REVERSE NUCLEAR CATARACT WITH EYEDROPS
(1) EV06 eyedrops to break lens disulfide bonds and soften the lens. This would allow (2) and (3) below to penetrate the lens. Contain lipoic acid choline ester. Bought by Novartis Pharma (which also has a huge surgical lens business) as an eyedrop to cure presbyopia for $465 million. Has already passed Phase II clinical trials in the US, but Novartis says it hasn't. Novartis has no plans to release this eyedrop which is therefore unavailable.
(2) AGE-crystallin crosslink breaker. Would contain phenacyl thiazolium bromide (PTB, synthetic) or chebula (Ayurveda, natural), or any other crosslink breaker. PTB was shown, at the University of Arkansas in 2008, to break crosslinks of AGEs with alpha-crystallin, and thereby reverse loss of chaperone function of alpha-crystallin. This discovery is the key to curing cataract blindness in 90 million people worldwide and alone is worth a Nobel Prize. The eye profession has no plans to use this discovery, therefore no intention to cure world blindness, and it is therefore unavailable.
(3) Alpha-crystallin stabilizers (sterols) This means lanosterol and other sterols. They have the ability to refold and stabilize alpha-crystallin liberated by (2) from its shackles to AGEs. Once stabilized, alpha-crystallin will then interfere with the electrostatic attraction between beta- and gamma- crystallin protein molecules by masking the electrical charges on their surfaces, thereby separating the molecules, and breaking up large molecular aggregates into smaller ones. This will restore optical transparency to the lens, curing the cataract.
Lanosterol eyedrops are available, but cannot work on alpha-crystallin until the lens is firstly softened, and the alpha-crystallin is secondly released from its bonds to AGEs (Steps (1) and (2)) above.